Merit Medical Systems (NASDAQ:MMSI) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Posted by Brenda Bartman on Jul 31st, 2026

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) had its target price raised by stock analysts at Needham & Company LLC from $90.00 to $101.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 21.18% from the stock’s previous close.

MMSI has been the subject of several other research reports. Weiss Ratings cut shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Wells Fargo & Company decreased their price target on shares of Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Barrington Research reduced their price objective on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a research note on Monday, April 20th. Wall Street Zen downgraded shares of Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 5th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $92.78.

Read Our Latest Analysis on Merit Medical Systems

Merit Medical Systems Trading Up 3.1%

Shares of MMSI opened at $83.35 on Friday. The firm has a market capitalization of $4.97 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 2.51 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. Merit Medical Systems has a 1-year low of $59.74 and a 1-year high of $94.75. The company has a 50-day moving average of $69.45 and a 200 day moving average of $71.69.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to the consensus estimate of $405.25 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, research analysts expect that Merit Medical Systems will post 3.62 EPS for the current year.

Insiders Place Their Bets

In other news, Director Lynne N. Ward sold 5,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian G. Lloyd bought 2,000 shares of Merit Medical Systems stock in a transaction that occurred on Thursday, May 7th. The stock was purchased at an average price of $62.62 per share, with a total value of $125,240.00. Following the purchase, the insider directly owned 2,000 shares in the company, valued at $125,240. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Merit Medical Systems

Hedge funds have recently added to or reduced their stakes in the business. State Street Corp lifted its holdings in shares of Merit Medical Systems by 1.5% in the 4th quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock valued at $196,645,000 after buying an additional 32,459 shares during the period. Conestoga Capital Advisors LLC boosted its holdings in Merit Medical Systems by 3.9% during the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock worth $149,407,000 after buying an additional 81,030 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in Merit Medical Systems by 12.7% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after buying an additional 234,682 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Merit Medical Systems by 7.0% during the 4th quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock valued at $116,963,000 after acquiring an additional 86,504 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Merit Medical Systems by 1.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock valued at $85,287,000 after purchasing an additional 12,285 shares during the period. 99.66% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

Positive Sentiment: Strong earnings and revenue beat: Second-quarter revenue rose 9.5% year over year to $418.8 million, surpassing the $405.3 million consensus estimate. Non-GAAP EPS increased 18% to $1.19, well above expectations of $0.96 and the year-ago result of $1.01. GAAP operating margin also improved to 14.4% from 12.3%. Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance
Positive Sentiment: Raised full-year guidance: Merit now expects fiscal 2026 adjusted EPS of $4.25 to $4.35, above the prior consensus estimate of $3.98. Revenue guidance remains approximately $1.6 billion, broadly in line with expectations, suggesting the primary upside is coming from earnings and margin performance. Merit Medical Raises 2026 Outlook on Strong Q2 Results
Positive Sentiment: Analyst confidence increased: Following the earnings beat and guidance increase, multiple analysts maintained Buy ratings and raised their price targets, reinforcing expectations for continued earnings growth. Analysts Increase Forecasts on Merit Medical Systems After Strong Q2 Results
Negative Sentiment: Cash generation softened: Year-to-date operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million. Investors may monitor whether this reflects temporary working-capital needs or a sustained pressure on cash conversion. Merit Medical Second-Quarter Results

About Merit Medical Systems

(Get Free Report)

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.